Kin Yip Tai Medicine-B announced its interim report for the year 2024, showing a loss of 210.9 million yuan during the period, a decrease from the loss of 549.7 million yuan in the same period last year. During the reporting period, the company did not distribute any dividends, nor did it have any plans for significant investments or capital assets. The company continues to focus on the research and development of biopharmaceuticals, especially for the treatment of metabolic and digestive system diseases. As of the end of the reporting period, the company's current assets were 594.4 million yuan, while current liabilities were 54.6 million yuan. The company's research and development costs increased by 68.2% compared to the same period last year, reaching 202.0 million yuan. The company did not distribute or declare any dividends during the reporting period.

Kin Yip Tai Medicine-B announced its interim report for the year 2024, showing a loss of 210.9 million yuan during the period, a decrease from the loss of 549.7 million yuan in the same period last year. During the reporting period, the company did not distribute any dividends, nor did it have any plans for significant investments or capital assets. The company continues to focus on the research and development of biopharmaceuticals, especially for the treatment of metabolic and digestive system diseases. As of the end of the reporting period, the company's current assets were 594.4 million yuan, while current liabilities were 54.6 million yuan. The company's research and development costs increased by 68.2% compared to the same period last year, reaching 202.0 million yuan. The company did not distribute or declare any dividends during the reporting period.